Chinook Therapeutics Inc KDNY

NAS: KDNY | ISIN: US16961L1061 10/08/2023

40,39 USD (+0,22%)

(+0,22%) 10/08/2023

Toon enkel gratis nieuws

17 juli 2023 · Moore Kuehn Encourages CWBR, KDNY, GHL, and DM Investors to Contact Law Firm · Persbericht

13 juni 2023 · Moore Kuehn Encourages KDNY, USX, CIR, and HMPT Investors to Contact Law Firm · Persbericht

10 juni 2023 · CHINOOK SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Chinook To Contact Him Directly To Discuss Their Options · Persbericht

16 maart 2021 · Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy · Persbericht

2 maart 2021 · Chinook Therapeutics to Present at Upcoming Investor Conferences · Persbericht

1 maart 2021 · Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases · Persbericht

23 februari 2021 · Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit · Persbericht

17 februari 2021 · Chinook Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference · Persbericht

2 februari 2021 · Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for CHK-336 for Treatment of Primary Hyperoxaluria · Persbericht

4 januari 2021 · Chinook Therapeutics to Present at Upcoming Investor Conferences · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe